Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Relay Therapeutics, Inc.RLAY · Entity 4044 | See remarks | August 26, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Relay Therapeutics, Inc.
Report date August 26, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 223,657 |
Reported balance
After 2026-08-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-26 · Sale · Disposed 4,508 · Balance 223,657 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2025. F2: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 6,102 shares underlying restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 6,102 shares underlying restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2026 Filed Aug 28, 2026 16:43 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 4,508 | $20.03 | $90,295.24 |
DisclosureSEC source: 0001193125-26-374645 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 223,657 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 6,102 shares underlying restricted stock units. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 20:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 748 | $18.61 | $13,920.28 |
DisclosureSEC source: 0001193125-26-326142 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,165 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 3,051 shares of restricted stock units ("RSUs") on July 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 6,102 shares underlying RSUs. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:12 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 3,056 | $6.95 | $21,239.20 |
DisclosureSEC source: 0001193125-26-294528 · ownership.xml · nonDerivative · entry 2 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 228,913 F4 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F5 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on January 2, 2026. F3 · balance_after: Includes 9,153 shares underlying restricted stock units. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:12 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 50,000 | $19.09 | $954,500.00 |
DisclosureSEC source: 0001193125-26-294528 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225,857 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.66 to $19.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 9,153 shares underlying restricted stock units. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 20:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 753 | $14.79 | $11,136.87 |
DisclosureSEC source: 0001193125-26-197415 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,857 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 3,051 shares of restricted stock units ("RSUs") on April 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 9,153 shares underlying RSUs. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 21:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,354 | $8.45 | $11,441.30 |
DisclosureSEC source: 0001193125-26-029412 · ownership.xml · nonDerivative · entry 3 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,610 F6 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of RSUs on January 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F7 · balance_after: Includes 12,204 shares underlying RSUs. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 11,684 | $7.62 | $89,032.08 |
DisclosureSEC source: 0001193125-26-029412 · ownership.xml · nonDerivative · entry 2 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,964 F4 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,394 shares of RSUs on January 26, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F5 · balance_after: Includes 17,710 shares underlying RSUs. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 475,000 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001193125-26-014110 · ownership.xml · derivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2036-01-12 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 13, 2026, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| December 31, 2025 Filed Jan 29, 2026 21:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 994 | $2.99 | $2,972.06 |
DisclosureSEC source: 0001193125-26-029412 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,463 F1 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on July 1, 2025. F3 · balance_after: Includes 108,919 shares underlying restricted stock units ("RSUs"). Read SEC document |
| October 29, 2025 Filed Oct 30, 2025 20:19 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 21,394 | $7.50 | $160,455.00 |
DisclosureSEC source: 0001193125-25-258595 · ownership.xml · nonDerivative · entry 2 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,469 F3 · price: This transaction was executed in multiple trades at prices ranging from $7.49 to $7.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 108,919 shares underlying RSUs. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:19 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 19,135 | $7.29 | $139,494.15 |
DisclosureSEC source: 0001193125-25-258595 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,863 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 47,897 shares of restricted stock units ("RSUs") on October 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 108,919 shares underlying RSUs. Read SEC document |
| July 29, 2025 Filed Jul 30, 2025 20:54 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 15,724 | $3.68 | $57,864.32 |
DisclosureSEC source: 0000950170-25-100367 · ownership.xml · nonDerivative · entry 2 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,998 F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,393 shares of RSUs on July 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4 · balance_after: Includes 156,816 shares underlying RSUs. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:54 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,359 | $3.74 | $5,082.66 |
DisclosureSEC source: 0000950170-25-100367 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,722 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on July 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 199,209 shares underlying RSUs. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 21:00 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 5,000 | $2.94 | $14,700.00 |
DisclosureSEC source: 0000950170-25-092315 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,081 F1 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025. F3 · balance_after: Includes 204,715 shares underlying RSUs. Read SEC document |
| April 30, 2025 Filed May 1, 2025 00:25 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 10,739 | $3.00 | $32,217.00 |
DisclosureSEC source: 0000950170-25-061367 · ownership.xml · nonDerivative · entry 2 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,081 F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,392 shares of RSUs on April 29, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4 · balance_after: Includes 204,715 shares underlying RSUs. Read SEC document |
| April 28, 2025 Filed May 1, 2025 00:25 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,364 | $3.17 | $4,323.88 |
DisclosureSEC source: 0000950170-25-061367 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,820 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,505 shares of restricted stock units ("RSUs") on April 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 247,107 shares underlying RSUs. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 20:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 247 | $2.84 | $701.48 |
DisclosureSEC source: 0000950170-25-047743 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,184 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 252,612 shares underlying RSUs. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 02:16 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 17,250 | $4.42 | $76,245.00 |
DisclosureSEC source: 0000950170-25-011335 · ownership.xml · nonDerivative · entry 4 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,431 F7 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 69,570 shares of RSUs on January 29, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F8 · balance_after: Includes 253,604 shares underlying RSUs. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 02:16 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 26,541 | $4.55 | $120,761.55 |
DisclosureSEC source: 0000950170-25-011335 · ownership.xml · nonDerivative · entry 3 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 419,681 F5 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 100,000 shares of RSUs on January 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F6 · balance_after: Includes 323,174 shares underlying RSUs. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 02:16 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 139,141 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-011335 · ownership.xml · nonDerivative · entry 2 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,222 F3 · shares: Represents RSUs granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F4 · balance_after: Includes 423,174 shares underlying RSUs. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 02:16 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,673 | $4.63 | $7,745.99 |
DisclosureSEC source: 0000950170-25-011335 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,081 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,505 shares of restricted stock units ("RSUs") on January 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 284,033 shares underlying RSUs. Read SEC document |
| January 10, 2025 Filed Jan 15, 2025 02:00 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0000950170-25-005568 · ownership.xml · derivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2035-01-09 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 10, 2025, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 01:35 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 16,576 | $4.45 | $73,763.20 |
DisclosureSEC source: 0000950170-25-002500 · ownership.xml · nonDerivative · entry 3 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,754 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $4.40 to $4.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 289,538 shares underlying RSUs. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 01:35 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 32,177 | $4.30 | $138,361.10 |
DisclosureSEC source: 0000950170-25-002500 · ownership.xml · nonDerivative · entry 2 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 325,330 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $4.26 to $4.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 289,538 shares underlying RSUs. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 01:35 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 32,156 | $4.15 | $133,447.40 |
DisclosureSEC source: 0000950170-25-002500 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 357,507 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 80,909 shares of restricted stock units ("RSUs") on December 31, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 289,538 shares underlying RSUs. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:05 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 400 | $4.38 | $1,752.00 |
DisclosureSEC source: 0000950170-24-141596 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,663 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on December 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 370,447 shares underlying RSUs. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 20:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,621 | $6.06 | $9,823.26 |
DisclosureSEC source: 0000950170-24-118985 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,063 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on October 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 371,439 shares underlying RSUs. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 20:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 245 | $7.51 | $1,839.95 |
DisclosureSEC source: 0000950170-24-110811 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 391,684 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on September 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 376,945 shares underlying RSUs. Read SEC document |
| July 31, 2024 Filed Jul 31, 2024 22:43 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 13,708 | $8.19 | $112,268.52 |
DisclosureSEC source: 0000950170-24-088813 · ownership.xml · nonDerivative · entry 4 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 391,929 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $7.96 to $8.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 377,937 shares underlying RSUs. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 22:43 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 15,128 | $8.28 | $125,259.84 |
DisclosureSEC source: 0000950170-24-088813 · ownership.xml · nonDerivative · entry 3 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,637 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $8.09 to $8.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 377,937 shares underlying RSUs. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 22:43 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 12,164 | $8.51 | $103,515.64 |
DisclosureSEC source: 0000950170-24-088813 · ownership.xml · nonDerivative · entry 2 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 420,765 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $8.22 to $8.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 377,937 shares underlying RSUs. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 22:43 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,359 | $8.85 | $12,027.15 |
DisclosureSEC source: 0000950170-24-088813 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,929 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,505 shares of restricted stock units ("RSUs") on July 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 377,937 shares underlying RSUs. Read SEC document |
| June 30, 2024 Filed Jul 1, 2024 20:41 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 2,108 | $5.54 | $11,678.32 |
DisclosureSEC source: 0000950170-24-079691 · ownership.xml · nonDerivative · entry 2 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,288 F3 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F4 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 28, 2024. F2 · balance_after: Includes 383,442 shares underlying RSUs. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:41 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 245 | $6.26 | $1,533.70 |
DisclosureSEC source: 0000950170-24-079691 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,180 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on June 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 383,442 shares underlying RSUs. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 00:01 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 20,450 | $7.06 | $144,377.00 |
DisclosureSEC source: 0000950170-24-069553 · ownership.xml · nonDerivative · entry 3 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,425 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $6.97 to $7.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 384,434 shares underlying RSUs. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 00:01 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 40,595 | $6.64 | $269,550.80 |
DisclosureSEC source: 0000950170-24-069553 · ownership.xml · nonDerivative · entry 2 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 452,875 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $6.56 to $6.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 384,434 shares underlying RSUs. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 00:01 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 19,864 | $6.47 | $128,520.08 |
DisclosureSEC source: 0000950170-24-069553 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 493,470 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 80,909 shares of restricted stock units ("RSUs") on May 31, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 384,434 shares underlying RSUs. Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 00:36 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,345 | $6.38 | $8,581.10 |
DisclosureSEC source: 0000950170-24-050152 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,334 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,505 shares of restricted stock units ("RSUs") on April 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 465,343 shares underlying RSUs. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 298 | $7.70 | $2,294.60 |
DisclosureSEC source: 0000950170-24-038654 · ownership.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 514,679 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 470,848 shares underlying RSUs. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:14 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,651 | $9.64 | $15,915.64 |
DisclosureSEC source: 0001209191-24-002474 · doc4.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 514,977 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on January 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 471,840 shares underlying RSUs. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:25 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001847 · doc4.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,628 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · balance_after: Includes 477,346 shares underlying RSUs. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:26 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 244 | $11.51 | $2,808.44 |
DisclosureSEC source: 0001209191-23-060000 · doc4.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,628 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on December 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 277,346 shares underlying RSUs. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:21 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,354 | $6.03 | $8,164.62 |
DisclosureSEC source: 0001209191-23-054027 · doc4.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,872 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,505 shares of restricted stock units ("RSUs") on October 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 278,338 shares underlying RSUs. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 20:32 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 244 | $8.38 | $2,044.72 |
DisclosureSEC source: 0001209191-23-050866 · doc4.xml · nonDerivative · entry 2 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,226 F4 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of RSUs on September 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F5 · balance_after: Prior to the reported transaction, the amount of securities beneficially owned by the reporting person was 318,470, with 284,835 shares underlying RSUs. F6 · balance_after: Includes 283,843 shares underlying RSUs. Read SEC document |
| July 28, 2023 Filed Jul 31, 2023 20:52 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,352 | $11.80 | $15,953.60 |
DisclosureSEC source: 0001209191-23-043850 · doc4.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,808 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on July 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 284,835 shares underlying RSUs. Read SEC document |
| June 30, 2023 Filed Sep 29, 2023 20:32 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 1,662 | $10.68 | $17,750.16 |
DisclosureSEC source: 0001209191-23-050866 · doc4.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,822 F1 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2023. F3 · balance_after: Includes 290,341 shares underlying restricted stock units ("RSUs"). Read SEC document |
| June 27, 2023 Filed Jun 28, 2023 21:12 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 244 | $12.12 | $2,957.28 |
DisclosureSEC source: 0001209191-23-040063 · doc4.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,160 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 991 shares of restricted stock units ("RSUs") on June 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 290,341 shares underlying RSUs. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 22:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 161,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033423 · doc4.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,404 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · balance_after: Includes 291,332 shares underlying RSUs. Read SEC document |
| April 28, 2023 Filed May 1, 2023 20:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 739 | $11.16 | $8,247.24 |
DisclosureSEC source: 0001209191-23-026280 · doc4.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,504 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,454 shares of restricted stock units ("RSUs") on April 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 132,564 shares underlying RSUs. Read SEC document |
| April 28, 2023 Filed Jun 1, 2023 22:21 UTC Amendment | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,657 | $11.16 | $18,492.12 |
DisclosureSEC source: 0001209191-23-033421 · doc4a.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,586 F1 · shares: This amendment is being filed to correct the number of shares sold to cover the reporting person's income tax withholding obligations upon the vesting of 5,504 shares of restricted stock units ("RSUs") on April 27, 2023, which was inadvertently understated in the reporting person's original Form 4. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Due to the error described above, the reporting person's original Form 4 incorrectly reported that the number of shares held by the reporting person was 157,504, including 132,564 shares underlying RSUs. As reported in this amendment, the correct number of shares held by the reporting person is 156,586, including 129,514 shares underlying RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.